Form 4: Gossamer Bio Director Receives Stock Option Grant

Director Sandra Milligan was granted 115,000 stock options as part of the Gossamer Bio Non-Employee Director Compensation Program.

Summary

• Director Sandra Milligan received a grant of 115,000 stock options on June 4, 2026.
• The options have an exercise price of $0.178 per share.
• The options are set to expire on June 3, 2036.
• Vesting occurs on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is subject to market volatility and the future performance of Gossamer Bio common stock.

Future Outlook

The options vest on the earlier of the first anniversary of the grant or the next annual meeting, contingent upon continued service.

Management Comments

• The award was made pursuant to the company's established Non-Employee Director Compensation Program.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with corporate performance.

Comparison to Industry Standards

• The grant structure follows standard industry practices for biotech companies regarding director compensation.
• Vesting schedules tied to annual meetings are common among publicly traded life sciences firms.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options on the earlier of June 4, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Gossamer Bio, GOSS, Form 4, Director Compensation, Stock Options, Insider Trading